These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 17049676

  • 21. Protection of BALB/c mice against Brucella melitensis 16 M infection induced by vaccination with live Escherchia coli expression Brucella P39 protein.
    Al-Mariri A.
    Vaccine; 2010 Feb 17; 28(7):1766-70. PubMed ID: 20036752
    [Abstract] [Full Text] [Related]

  • 22. Improved influenza viral vector based Brucella abortus vaccine induces robust B and T-cell responses and protection against Brucella melitensis infection in pregnant sheep and goats.
    Mailybayeva A, Yespembetov B, Ryskeldinova S, Zinina N, Sansyzbay A, Renukaradhya GJ, Petrovsky N, Tabynov K.
    PLoS One; 2017 Feb 17; 12(10):e0186484. PubMed ID: 29023541
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Pathogenicity and protective activity in pregnant goats of a Brucella melitensis Deltaomp25 deletion mutant.
    Edmonds MD, Cloeckaert A, Hagius SD, Samartino LE, Fulton WT, Walker JV, Enright FM, Booth NJ, Elzer PH.
    Res Vet Sci; 2002 Jun 17; 72(3):235-9. PubMed ID: 12076120
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The protein moiety of Brucella abortus outer membrane protein 16 is a new bacterial pathogen-associated molecular pattern that activates dendritic cells in vivo, induces a Th1 immune response, and is a promising self-adjuvanting vaccine against systemic and oral acquired brucellosis.
    Pasquevich KA, García Samartino C, Coria LM, Estein SM, Zwerdling A, Ibañez AE, Barrionuevo P, Oliveira FS, Carvalho NB, Borkowski J, Oliveira SC, Warzecha H, Giambartolomei GH, Cassataro J.
    J Immunol; 2010 May 01; 184(9):5200-12. PubMed ID: 20351187
    [Abstract] [Full Text] [Related]

  • 27. Immunogenicity and protective efficacy of Brucella abortus recombinant protein cocktail (rOmp19+rP39) against B. abortus 544 and B. melitensis 16M infection in murine model.
    Tadepalli G, Singh AK, Balakrishna K, Murali HS, Batra HV.
    Mol Immunol; 2016 Mar 01; 71():34-41. PubMed ID: 26826463
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Differential immunogenicity and protective efficacy of DNA vaccines expressing proteins of Mycobacterium tuberculosis in a mouse model.
    Fan X, Gao Q, Fu R.
    Microbiol Res; 2009 Mar 01; 164(4):374-82. PubMed ID: 17764918
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Evaluation of immune responses induced by polymeric OMP25-BLS Brucella antigen.
    Yousefi S, Abbassi-Daloii T, Sekhavati MH, Tahmoorespur M.
    Microb Pathog; 2018 Feb 01; 115():50-56. PubMed ID: 29253594
    [Abstract] [Full Text] [Related]

  • 33. Identification and characterization of Brucella ovis immunogenic proteins using two-dimensional electrophoresis and immunoblotting.
    Teixeira-Gomes AP, Cloeckaert A, Bézard G, Bowden RA, Dubray G, Zygmunt MS.
    Electrophoresis; 1997 Aug 01; 18(8):1491-7. PubMed ID: 9298663
    [Abstract] [Full Text] [Related]

  • 34. [Novel vaccines against M. tuberculosis].
    Okada M.
    Kekkaku; 2006 Dec 01; 81(12):745-51. PubMed ID: 17240920
    [Abstract] [Full Text] [Related]

  • 35. Development and evaluation of in murine model, of an improved live-vaccine candidate against brucellosis from to Brucella melitensis vjbR deletion mutant.
    Li Z, Wang S, Zhang H, Xi L, Zhang J, Zhang X, Zhou Q, Yi J, Li M, Zhang W, Zhang J.
    Microb Pathog; 2018 Nov 01; 124():250-257. PubMed ID: 30149131
    [Abstract] [Full Text] [Related]

  • 36. Immunoproteomic analysis of Brucella melitensis and identification of a new immunogenic candidate protein for the development of brucellosis subunit vaccine.
    Yang Y, Wang L, Yin J, Wang X, Cheng S, Lang X, Wang X, Qu H, Sun C, Wang J, Zhang R.
    Mol Immunol; 2011 Oct 01; 49(1-2):175-84. PubMed ID: 21943783
    [Abstract] [Full Text] [Related]

  • 37. Survey of Omp19 immunogenicity against Brucella abortus and Brucella melitensis: influence of nanoparticulation versus traditional immunization.
    Abkar M, Lotfi AS, Amani J, Eskandari K, Ramandi MF, Salimian J, Brujeni GN, Alamian S, Kamali M, Koushki H.
    Vet Res Commun; 2015 Dec 01; 39(4):217-28. PubMed ID: 26395469
    [Abstract] [Full Text] [Related]

  • 38. Immunization of mice with a novel recombinant molecular chaperon confers protection against Brucella melitensis infection.
    Ghasemi A, Jeddi-Tehrani M, Mautner J, Salari MH, Zarnani AH.
    Vaccine; 2014 Nov 20; 32(49):6659-66. PubMed ID: 25240754
    [Abstract] [Full Text] [Related]

  • 39. Minor nucleotide substitutions in the omp31 gene of Brucella ovis result in antigenic differences in the major outer membrane protein that it encodes compared to those of the other Brucella species.
    Vizcaíno N, Kittelberger R, Cloeckaert A, Marín CM, Fernández-Lago L.
    Infect Immun; 2001 Nov 20; 69(11):7020-8. PubMed ID: 11598077
    [Abstract] [Full Text] [Related]

  • 40. Nasal immunization with recombinant Brucella melitensis bp26 and trigger factor with cholera toxin reduces B. melitensis colonization.
    Yang X, Walters N, Robison A, Trunkle T, Pascual DW.
    Vaccine; 2007 Mar 08; 25(12):2261-8. PubMed ID: 17239499
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.